Five biotech and pharma stocks to watch

FiercePharma's sister publication FierceBiotech asked prominent market analysts to weigh in on major biopharma milestones on the near horizon. So Dr. Simos Simeonidis, the senior biotech analyst for Rodman & Renshaw, scanned the radar for key upcoming events. He focuses on five biotech and pharma companies at important crossroads in their development. Their success or failure at this juncture will have a big impact on their future. Article

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.